Trend
DailyDowntrend (confirmed)
4 hourSymmetric Triangle
1 hourSymmetric Triangle
15 minLeaning Bullish
5 minStrong Bearish
Daily trend turns up above $3.69
Key levels
Resistance$3.69
Resistance$3.38
Support$2.70
Support$2.32
Latest news & SEC filings
SEC FilingLexeo Therapeutics, Inc. filed a shelf registration for future offerings (Form S-3)
All LXEO news →Lexeo Therapeutics is a clinical-stage gene therapy company. It develops treatments for genetic cardiac and neurological diseases, with lead programs LX2006 and LX2020. The company operates in the United States and relies on third-party manufacturers and research organizations.
Based on the company's 10-K filed Mar 30, 2026.
Nasdaq · Healthcare
SEPT Low Target
$7.65
SEPT Mid Target
$9.00
SEPT High Target
$10.35
Analyst Consensus
$9.00
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for LXEO.
Start Free Trial →Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$7.58
17
Moat Score
NONE
4/9
Piotroski Score
2.3
Altman Z-Score
Insider Signal
SELLING
0 buys / 6 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
ACCUMULATING
Short Squeeze Risk
LOW
Signal: NEUTRAL
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Bhalla Narinder Pal | officer | Buy | 2,714 | $10K | Sep 14, 2026 |
| Otero Jose Manuel | officer | Buy | 2,110 | $6K | Sep 14, 2026 |
| Townsend Richard Nolan | director officer | Buy | 2,306 | $6K | Sep 14, 2026 |
| Otero Jose Manuel | officer | Sale | 1,302 | $7K | May 18, 2026 |
| Townsend Richard Nolan | director officer | Sale | 3,342 | $17K | May 18, 2026 |
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
39.81%
FCF Growth YoY
-21.2%
Revenue Trend
UNKNOWN
SEPT Investing tracks real-time dark pool institutional trades for LXEO, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:00:02 | $2.91 | 3,022 | $$9K | SELL |
| 20:59:58 | $2.91 | 1,400 | $$4K | SELL |
| 20:59:49 | $2.91 | 1,760 | $$5K | MIDPOINT |
| 20:57:42 | $2.92 | 1,000 | $$3K | MIDPOINT |
| 20:57:19 | $2.92 | 1,000 | $$3K | BUY |
5 dark pool trades shown · $$24K preview volume
Real-time institutional flow, block trades, and net positioning
SEPT Investing provides real-time options flow tracking for LXEO, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| PUT | $4 | May 21 | 190 | $$260 | 2 | SWEEP |
| PUT | $4 | May 21 | 190 | $$260 | 2 | SWEEP |
| PUT | $4 | May 21 | 190 | $$260 | 2 | SWEEP |
3 options trades shown · 0% calls
Unusual activity, GEX levels, max pain, and dealer positioning
SEPT's Trading AI has generated a free, downloadable PDF research report for Lexeo Therapeutics, Inc. (LXEO) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (2 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →Lexeo Therapeutics, Inc. (LXEO) is at $2.91, down 5.21% (-$0.16) at the Nov 12, 2026 close.
Latest LXEO news — Oct 29, 2026: Lexeo Therapeutics, Inc. filed a shelf registration for future offerings (Form S-3)
The average analyst price target for LXEO is $9.00, ranging from $9 to $9, based on 1 analysts. Latest: JP Morgan maintains on Jun 25, 2026.
Analyst ratings for LXEO: 0 Buy, 1 Hold, 0 Sell — consensus Hold.
LXEO last reported on Aug 12, 2026: EPS -$0.30 vs -$0.29 expected — a miss of 5.2%.
LXEO does not currently pay a dividend.
Support: $2.70, $2.32, $1.45. Resistance: $3.38, $3.69, $4.01.
Insider activity: SELLING, 0 buys and 6 sells in the last 90 days.
Oct 29, 2026: Lexeo Therapeutics, Inc. filed a shelf registration for future offerings (Form S-3)